ArriVent BioPharma, Inc.

For the period ended Sep 30, 2026. Filed Nov 9, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 9, 2026

AVBP$13.49-4.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Stockholders’ Equity (Deficit

(in thousands, except share data)


· · · · · · · · · · · Accumulated · · · · ·
· · · · · · · · Additional · · Other · · · · · ·
· · · Common stock · · paid-in · · Comprehensive · · Accumulated · ·
· · Shares · · Amount · · capital · · (Loss) · · deficit · · Total
Balance January 1, 2026	42,452,251	$4	$711,847	$14	$(404,641)	$307,224
Issuance of common stock, net of issuance costs of $2,418	2,425,495	1	54,724	—	—	54,725
Exercise of stock options	31,195	—	150	—	—	150
Exercise of pre-funded warrants	400,000	—	—	—	—	—
Stock-based compensation expense	—	—	5,485	—	—	5,485
Unrealized loss on investments	—	—	—	(284)	—	(284)
Net loss	—	—	—	—	(43,320)	(43,320)
Balance March 31, 2026	45,308,941	5	772,206	(270)	(447,961)	323,980
Issuance of common stock, net of issuance costs of $2,509	2,932,823	—	85,234	—	—	85,234
Exercise of stock options	77,827	—	852	—	—	852
Stock-based compensation expense	—	—	6,665	—	—	6,665
Unrealized gain on investments	—	—	—	3	—	3
Net loss	—	—	—	—	(49,893)	(49,893)
Balance, June 30, 2026	48,319,591	5	864,957	(267)	(497,854)	366,841
Issuance of common stock, net of issuance costs of $1,574	1,960,142	—	59,658	—	—	59,658
Exercise of stock options	32,437	—	605	—	—	605
Exercise of pre-funded warrants	900,000	—	—	—	—	—
Stock-based compensation expense	—	—	6,884	—	—	6,884
Unrealized loss on investments	—	—	—	(199)	—	(199)
Net loss	—	—	—	—	(40,313)	(40,313)
Balance, September 30, 2026	51,212,170	$5	$932,104	$(466)	$(538,167)	$393,476

CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

(in thousands, except share data)


· · · · · · · · · · · Accumulated · · · · ·
· · · · · · · · Additional · · Other · · · · · ·
· · · Common stock · · paid-in · · Comprehensive · · Accumulated · ·
· · Shares · · Amount · · capital · · (Loss) · · deficit · · Total
Balance January 1, 2025	33,706,765	$3	$496,195	$(211)	$(238,333)	$257,654
Issuance of common stock, net of issuance costs of $858	264,458	1	6,516	—	—	6,517
Exercise of stock options	69,773	—	293	—	—	293
Stock-based compensation expense	—	—	2,271	—	—	2,271
Unrealized gain on investments	—	—	—	194	—	194
Net loss	—	—	—	—	(64,387)	(64,387)
Balance March 31, 2025	34,040,996	4	505,275	(17)	(302,720)	202,542
Issuance of common stock, net of issuance costs of $2,395	3,428,766	—	75,341	—	—	75,341
Exercise of stock options	20,677	—	76	—	—	76
Stock-based compensation expense	—	—	3,311	—	—	3,311
Unrealized loss on investments	—	—	—	(1)	—	(1)
Net loss	—	—	—	—	(31,399)	(31,399)
Balance, June 30, 2025	37,490,439	4	584,003	(18)	(334,119)	249,870
Issuance of common stock, net of issuance costs of $5,825	3,339,581	—	86,091	—	—	86,091
Exercise of stock options	22,292	—	74	—	—	74
Stock-based compensation expense	—	—	3,716	—	—	3,716
Unrealized gain on investments	—	—	—	224	—	224
Net loss	—	—	—	—	(34,978)	(34,978)
Balance, September 30, 2025	40,852,312	$4	$673,884	$206	$(369,097)	$304,997

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.